Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 12/20 | 0.51 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | RHEB | Q15382 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10029169 | 0.88 | CHEK2 (0.53) | CHEK2NR4A2HDAC3HDAC1HDAC2 | |
| SCHEMBL1840143 | 0.88 | CHEK2 (0.53) | CHEK2NR4A2HDAC3HDAC1HDAC2 | |
| SCHEMBL1841823 | 0.87 | CHEK2 (0.50) | CHEK2NR4A2HDAC3HDAC1HDAC2 | |
| SCHEMBL1840661 | 0.87 | CHEK2 (0.50) | CHEK2NR4A2HDAC3HDAC1HDAC8 | |
| SCHEMBL10029170 | 0.87 | CHEK2 (0.50) | CHEK2NR4A2HDAC3HDAC1HDAC2 | |
| SCHEMBL10029164 | 0.87 | CHEK2 (0.50) | CHEK2NR4A2HDAC3HDAC1HDAC8 | |
| SCHEMBL10029163 | 0.86 | CHEK2 (0.49) | CHEK2NR4A2HDAC3HDAC1HDAC2 | |
| SCHEMBL1842525 | 0.85 | CHEK2 (0.48) | CHEK2NR4A2HDAC3HDAC1HDAC2 | |
| SCHEMBL1838720 | 0.84 | CHEK2 (0.47) | CHEK2NR4A2HDAC3HDAC1HDAC2 | |
| SCHEMBL10029165 | 0.83 | CHEK2 (0.50) | CHEK2NR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168665-B2 | Substituted 2-phenyl-benzimidazoles and their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2012-05-01 | — | — | US | disclosed |
| US-8168665-B2 | Substituted 2-phenyl-benzimidazoles and their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2012-05-01 | — | — | US | disclosed |
| US-20090239915-A1 | Substituted 2-phenyl-benzimidazoles and their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2009-09-24 | — | — | US | disclosed |
| US-20090239915-A1 | Substituted 2-phenyl-benzimidazoles and their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2009-09-24 | — | — | US | disclosed |
| WO-2008037381-A1 | SUBSTITUTED 2-PHENYL-BENZIMIDAZOLES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239915-A1 | Substituted 2-phenyl-benzimidazoles and their use as pharmaceuticals | NOS2, NOS3, NOS1 | CHEK2 4134/4885NR4A2 983/4885HDAC3 771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.